资料显示，隽泰控股有限公司("公司")是一家于百慕大注册成立之有限公司,及其已发行股份于一九九六 年在香港联合交易所有限公司主板上市(股票编号:630)。公司透过其附属公司主要从事制造及销售医疗 设备产品、制造及销售塑料模具产品及制造、销售及分销数据媒体产品。于二零一一年十月,公司透过 收购Titron集团从而开拓制造及销售医疗设备产品、制造及销售塑料模具产品业务。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 来源：金融界 财务数据显示，截至2024年12月31日，隽泰控股实现营业总收入3499.69万元，同比增长10.07%；归母 净利润-114.18万元，同比增长55.21%；毛利率36.89%，资产负债率62.26%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.87倍，行业中值0.4倍。隽泰控股 市盈率-36.1倍，行业排名第65位；其他京玖康疗（00648.HK）为0.38倍、巨星医疗控股（02393.HK） 为0.42倍、永胜医疗（01612.HK）为3.87倍、环球医疗（02666 ...

机构评级方面，目前暂无机构对该股做出投资评级建议。 5月23日，截至港股收盘，恒生指数上涨0.24%，报23601.26点。隽泰控股（00630.HK）收报0.06港元/ 股，上涨42.86%，成交量6.53万股，成交额3840港元，振幅0.0%。 最近一个月来，隽泰控股累计跌幅16%，今年来累计跌幅65%，跑输恒生指数17.37%的涨幅。 财务数据显示，截至2024年12月31日，隽泰控股实现营业总收入3499.69万元，同比增长10.07%；归母 净利润-114.18万元，同比增长55.21%；毛利率36.89%，资产负债率62.26%。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 本文源自：金融界 作者：行情君 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-19.66倍，行业中值0.31倍。隽泰控 股市盈率-32.96倍，行业排名第65位；其他巨星医疗控股（02393.HK）为0.25倍、京玖康疗 （00648.HK）为0.38倍、永胜医疗（01612.HK）为4.01倍、环球医疗（02666.HK）为4.58倍、瑞慈医疗 （01526.HK）为5 ...

Financial Performance - The total revenue of AMCO United Holding Limited increased by HK$3.5 million or 10.2%, from HK$34.3 million in 2023 to HK$37.8 million in 2024[17]. - The loss for the year decreased from HK$2.75 million in 2023 to HK$1.23 million in 2024, representing a reduction of approximately 55.4%[6]. - The equity attributable to owners of the Company decreased slightly from HK$61.36 million in 2023 to HK$60.13 million in 2024[6]. - The current ratio improved from 2.2 in 2023 to 2.3 in 2024, indicating better short-term financial health[6]. - The return on total assets improved from (1.6%) in 2023 to (0.8%) in 2024, reflecting a reduction in losses relative to total assets[6]. - Gross profit decreased by HK$0.9 million or 6.1% to HK$13.9 million, with a gross profit margin decline of 6.2 percentage points to 36.9%[27]. - The overall loss attributable to owners of the Company decreased by HK$1.6 million or 57.1% to HK$1.2 million compared to a loss of HK$2.8 million in 2023[30]. Business Segments - The Group's Money Lending Business generated stable income in 2024, while the Securities Investment segment recorded a loss[19]. - Medical Products revenue rose by HK$3.7 million or 16.9% to HK$25.6 million, accounting for 67.6% of the Group's total revenue[35]. - The segment profit for Medical Products increased to HK$4.2 million in 2024 from HK$3.3 million in 2023, aided by the reversal of impairment loss under ECL[39]. - The segment loss for Plastic Products in 2024 was approximately HK$1,546,000, an increase of HK$717,000 compared to a loss of approximately HK$829,000 in 2023[109]. - The segment profit from Money Lending amounted to HK$7.3 million, down from HK$14.7 million in 2023[114]. Operational Strategies - The Group plans to maintain liquidity by effectively managing working capital and controlling costs in response to market uncertainties[22]. - The Group aims to optimize its business portfolio and explore new growth potentials to maximize shareholder value[23]. - The Group is focused on dynamic performance evaluation and asset reallocation to adapt to market changes and enhance operational efficiency[24]. - The Group employs a just-in-time production strategy to enhance competitiveness, allowing for quick adjustments in production volumes and product mix according to market demand[85]. - The procurement department monitors raw material consumption and adjusts procurement based on sales orders and forecasts to minimize storage costs and obsolete stock risks[85]. Customer Engagement and Market Development - The Group is actively exploring potential business opportunities to expand its customer base in the Medical Devices Business[18]. - The customer base mainly consists of users and distributors in the PRC, including retailers and trading companies[51][54]. - The Group is actively seeking new opportunities to broaden its customer base through various channels, including referrals and business events[52][53]. Investment and Financial Management - The Group recorded loan interest income of HK$11.2 million from its Money Lending, representing a decrease of HK$0.6 million or 5.1% compared to HK$11.8 million for the previous year, accounting for 29.7% of the Group's total revenue[114]. - The Group experienced net impairment losses of approximately HK$3.0 million for expected credit losses and write-offs on loan and interest receivables for the year ended December 31, 2024[120]. - The Group intends to diversify its investment portfolio to reduce concentration and investment risks in light of recent market volatility[137]. - The Group has a policy for assessing credit risk based on close monitoring, including aging analysis and past collection history[134]. Governance and Management - The Group's management team includes experienced professionals with backgrounds in finance, human resources, and e-commerce[163][164][173]. - The Board consists of two Executive Directors and three Independent Non-executive Directors, ensuring a balanced composition[178]. - The Company complied with all provisions of the Corporate Governance Code throughout the year ended December 31, 2024, with certain disclosed deviations[175]. - Each Executive Director is suitably qualified and possesses sufficient experience to effectively carry out their duties[191]. Quality Control and Production - The Group emphasizes consistent product quality through a stringent quality control system to meet relevant medical device standards[45][48]. - Quality control measures are implemented throughout the production process to ensure that finished products meet safety standards and customer specifications[78]. - The Group's production process includes manual testing and assembly steps to ensure the quality of medical devices before packaging[90]. Future Outlook - The Board anticipates stable market demand for medical products, particularly lancet piping parts and devices, due to the increasing prevalence of diabetes, projected to affect 783 million adults by 2045[103]. - The demand for medical products is expected to grow due to increased public health awareness post-COVID-19, with stable revenue anticipated from pandemic-related products[106].

普利制药股债暴跌。 A股市场今天上午窄幅震荡。行业板块和赛道方面，钢铁、互联网、银行、电力等板块盘中涨幅居前。 A股市场今天有一只进入退市整理期的股票，为普利退(普利制药，300630.SZ)，上午该股一度暴跌超过70%。 港股市场今天上午表现亦相对平淡，主要指数波动幅度不大。 A股市场上午窄幅震荡 A股市场今天上午窄幅震荡。 行业板块和赛道方面，钢铁、互联网、银行、电力等板块盘中涨幅居前。房地产、旅游、家居用品等板块盘中跌幅居前。 金风科技今天上午一度大涨近9%。 进入退市整理期普利制药盘中暴跌77.51% 普利制药今日进入退市整理期，证券简称变更为"普利退"。上午，普利退暴跌，盘中最大跌幅一度达到77.51%，后跌幅有所收窄。 与此同时，普利制药发行的可转债今天上午也出现暴跌，盘中跌幅一度达到33.72%，目前证券简称已变为"普利转退"。 概念板块方面，PEEK材料概念板块大幅上涨。肯特股份（301591）盘中一度触及"20cm"涨停，新瀚新材（301076）盘中一度涨超16%，中研股份、中欣 氟材（002915）、南京聚隆（300644）等股票盘中跟涨。 电子纸、Sora概念、云游戏等概念板块盘中涨幅亦 ...

PEEK材料概念股领涨两市。 新ST股密集跌停 4月28日早盘，普利退（300630.SZ）开盘跌超77%，午间收盘仍跌超70%。早盘，由于普利退波动幅度巨大，盘中一度两次被临时停牌。 | 代码 | 名称 | 实施日期 | 实施前简 | 实施后间 | | --- | --- | --- | --- | --- | | | | | 126 | 125 | | 002529 | 海源复材 | 2025-04-29 | 海源复材 | *ST海浪 | | 002214 | 大立科技 | 2025-04-29 | 大立科技 | *ST大 ▽ | | 002076 | 星光股份 | 2025-04-29 | 星光股份 | *ST星元 | | 002656 | ST學堂 | 2025-04-29 | ST 章 | *ST = 白 | | 600355 | 精伦电子 | 2025-04-29 | 精伦电子 | *ST精伦 | | 600421 | 束候控股 | 2025-04-29 | 衣候容胎 | *ST华顺 | | 605081 | 太和水 | 2025-04-29 | 太和水 | *ST太和 | | 600636 | ...

4月18日晚间，深交所发布《关于海南普利制药股份有限公司股票及可转换公司债券终止上市的公 告》。根据公告，深交所对*ST普利股票及可转债作出终止上市决定。 重大财务造假 2025年3月21日，*ST普利收到中国证监会出具的《行政处罚决定书》。 根据《行政处罚决定书》查明的事实，公司2021年、2022年年度报告存在虚假记载，同时，2021年、 2022年虚假记载的利润总额金额合计达6.69亿元，且占该两年披露的年度利润总额合计金额的73.83%。 具体来看： 2021年至2022年，普利制药通过虚构成品药和原料药销售业务的方式，虚假确认药品销售收入和利润。 其中，2021年多计营业收入436,004,495.01元，占当年披露营业收入的28.90%，对应营业成本 128,197,101.98元，多计利润总额290,175,562.61元，占当年披露利润总额的62.06%；2022年多计营业收 入455,776,233.78元，占当年披露营业收入的25.23%，对应营业成本69,013,203.17元，多计利润总额 379,066,467.07元，占当年披露利润总额的86.36%。 同期，普利制药将其开展的不具 ...

4月14日，截至港股收盘，恒生指数上涨2.4%，报21417.4点。隽泰控股（00630.HK）收报0.062港元/ 股，上涨12.73%，成交量8万股，成交额5050港元，振幅3.64%。 最近一个月来，隽泰控股累计跌幅22.54%，今年来累计跌幅54.17%，跑输恒生指数4.26%的涨幅。 财务数据显示，截至2024年12月31日，隽泰控股实现营业总收入3499.69万元，同比增长10.07%；归母 净利润-114.18万元，同比增长55.21%；毛利率36.89%，资产负债率62.26%。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-22.01倍，行业中值0.27倍。隽泰控 股市盈率-43.16倍，行业排名第60位；其他巨星医疗控股（02393.HK）为0.17倍、京玖康疗 （00648.HK）为0.38倍、永胜医疗（01612.HK）为3.49倍、环球医疗（02666.HK）为4.34倍、中国再生 医学（08158.HK）为4.97倍。 资料显示，隽泰控股有限公司("公司")是一家于百慕大注册成立之有限公司,及其已发行股份于一九九六 年在香港联合交易所有限公司主板上市(股票编号:63 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 截至二零二四年十二月三十一日止年度之業績公告 業績 雋泰控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，本公司及其附 屬公司（以下統稱為「本集團」）截至二零二四年十二月三十一日止年度經審核綜 合業績連同去年之比較數字如下。 綜合損益及其他全面收益表 截至二零二四年十二月三十一日止年度 | | | 二零二四年 | 二零二三年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 持續經營業務 | | | | | 收入 | 5 | 37,792 | 34,333 | | 銷售成本 | | (23,852) | (19,525) | | 毛利 | | 13,940 | 14,808 | | 其他收入及其他收益或虧損 | 6 | (1,554) | (8,115) | | 分銷成本 | | (3 ...

普利制药(300630)可能触及重大违法退市情形，将根据最终决定，依规实施退市。 1月5日，普利制药公告称，收到中国证监会作出的《行政处罚事先告知书》(以下简称《告知书》)，认 定公司披露的2021年年报、2022年年报存在虚假记载，同时可能触及《创业板股票上市规则》规定的重 大违法强制退市情形，将自1月7日起被实施重大违法强制退市风险警示。后续将根据最终作出的行政处 罚决定，依规实施退市。 但上述更正事项未得到会计师事务所认可。公司2023年度审计机构天健会计师事务所（特殊普通合伙） 因无法核实前期差错更正事项是否完整、更正金额是否准确，对公司2023年年报出具保留意见的审计报 告。 与此同时，根据《深圳证券交易所上市公司自律监管指引第15号——可转换公司债券》规定，若上市公 司股票被终止上市的，可转债同步终止上市或者挂牌。 严重财务造假触及重大违法强制退市情形 因涉嫌信息披露违法违规，普利制药被中国证监会立案调查。公司于2025年1月4日收到中国证监会下发 的《告知书》。根据《告知书》认定的事实，公司2021年、2022年年度报告存在虚假记载，同时，2021 年、2022年虚假记载的营业收入金额合计约10 ...

Revenue and Profitability - For the six months ended 30 June 2024, the Group's revenue decreased by HK$1.3 million or 5.6% to HK$22.0 million compared to HK$23.3 million in the same period last year[4] - Gross profit increased by HK$1.9 million or 38.8% to HK$6.8 million, with a gross profit margin rising by 9.7 percentage points to 30.8%[4] - The Medical Products Business generated revenue of HK$16.3 million, accounting for 74.2% of the Group's total revenue, remaining stable compared to HK$16.4 million in the previous year[6] - The Money Lending Business recorded loan interest income of HK$5.7 million, a decrease of HK$0.3 million or 5.0% from HK$6.0 million in the prior year, representing 25.8% of total revenue[14] - The overall loss attributable to owners of the Company was HK$25.4 million, a decrease of HK$4.3 million compared to a loss of HK$29.7 million in the corresponding period of 2023[5] - The segment profit of the Medical Products Business increased to HK$1.7 million from HK$1.4 million in the previous year, indicating effective cost management strategies[9] - The Group's lending business segment reported a loss of HK$700,000 for the period, an improvement from a loss of HK$800,000 in the same period last year[15] - The loss before income tax improved to HK$25,429,000, a reduction of 14.8% from HK$29,673,000 in the previous year[51] Expenses and Cost Management - Distribution costs decreased by HK$0.5 million to HK$2.2 million, while administrative expenses decreased by HK$4.2 million or 41.6% to HK$5.9 million due to stringent cost control[5] - Other losses during the period amounted to HK$22.9 million, compared to a loss of HK$20.3 million in the same period last year, influenced by fair value changes in securities investments[4] - The Group's securities investment segment incurred a net unrealised and realised loss of HK$22.9 million for the six months ended June 30, 2024, compared to a loss of HK$11.0 million for the same period last year[15] Financial Position - As of June 30, 2024, the Group's consolidated net asset was approximately HK$35.9 million, a decrease of approximately HK$25.5 million from HK$61.4 million as of December 31, 2023[23] - The Group's total cash and bank balances amounted to approximately HK$4.6 million as of June 30, 2024, down HK$3.1 million from HK$7.7 million as of December 31, 2023[23] - The Group's gearing ratio increased to 73.2% as of June 30, 2024, compared to 37.8% as of December 31, 2023[23] - The Group's current ratio was 2.0 as of June 30, 2024, down from 2.2 as of December 31, 2023[24] - The Group had no borrowings from financial institutions as of June 30, 2024, and December 31, 2023[23] - The Group had bond payables of HK$30.0 million as of June 30, 2024, unchanged from December 31, 2023[23] - The Group's total trade and other receivables as of June 30, 2024, amounted to HK$94,586,000, down from HK$108,272,000 as of December 31, 2023, indicating a reduction of about 12.6%[84] - Trade receivables from contracts with customers were HK$41,798,000 as of June 30, 2024, compared to HK$45,294,000 as of December 31, 2023, reflecting a decrease of approximately 7.3%[84] Investment Strategy - The Group aims to enhance competitiveness by revitalizing its scaffolding business and focusing on segments with higher profit margins, such as money lending operations[18] - The Group will continue to maintain a diversified investment portfolio to minimize potential financial risks and will conduct constant performance appraisals to evaluate ongoing business development[20] - The Group's investment strategy focuses on maximizing sustained long-term returns while maintaining stable growth in traditional business areas[19] - As of June 30, 2024, the Group held 27 listed equity securities in Hong Kong with a fair value of HK$25.3 million, and intends to diversify its investment portfolio to reduce concentration and investment risks[15] Share Options and Corporate Governance - The company has granted share options totaling 3,724,000 shares to each of the three directors, representing approximately 0.38% of the issued share capital as of June 30, 2024[33] - The share options were granted under the Share Option Scheme at an exercise price of HK$0.435 per share, established on May 4, 2020[34] - The maximum number of shares that may be issued upon the exercise of all share options under the Share Option Scheme is capped at 10% of the issued share capital on the date of approval[39] - The Share Option Scheme is valid for ten years and will expire on June 29, 2025[39] - The company has complied with all provisions of the Corporate Governance Code for the six months ended June 30, 2024[50] - The audit committee consists of three independent non-executive directors who reviewed the accounting principles and practices adopted by the group[50] Employee and Management Information - The Group's employee count remained stable at 30 as of June 30, 2024, consistent with December 31, 2023[29] - The remuneration for key management personnel decreased slightly from HK$426,000 in the previous year to HK$408,000 for the six months ended June 30, 2024[98] Other Financial Information - The Group incurred no depreciation charge on property, plant, and equipment for the six months ended June 30, 2024, compared to HK$140,000 for the same period in 2023[81] - The Group allows a credit period of up to 90 days to its trade customers, consistent with the previous period[85] - The Group's loan receivables are interest-bearing at rates ranging from 4% to 12% per annum, consistent with the previous period[86] - The total trade and other payables decreased from HK$76,457,000 as of December 31, 2023, to HK$66,698,000 as of June 30, 2024, a decrease of approximately 12.7%[88]